文献速递脊柱关节炎

生物制剂改善病情抗风湿药与中轴型脊柱关节炎疾病修饰:因果推断视角的综述

Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference.
PubMed 文献 · RMD Open · 2021-01-01

中轴型脊柱关节炎(axSpA)的脊柱结构损伤常用mSASSS评分量化,生物制剂改善病情抗风湿药(bDMARDs)在随机对照试验中证实可抑制炎症,但难以评估结构进展。本文基于因果推断原则综述观察性研究,区分混杂效应与因果效应,认为bDMARDs可能通过抗炎作用间接影响脊柱放射学进展。

要点

  • bDMARDs在RCT中证实可抑制axSpA炎症,但RCT难以评估mSASSS结构变化。
  • 观察性研究需满足exchangeability、positivity、consistency假设方可推断因果。
  • bDMARDs可能通过抗炎作用间接干扰axSpA脊柱放射学进展。

核心结论

  • bDMARDs可能通过其对炎症的作用间接干扰axSpA的脊柱放射学进展。

研究设计与样本

  • 本文为综述,基于因果推断原则(反事实推理中的exchangeability、positivity、consistency假设)回顾评估bDMARDs对脊柱放射学进展影响的观察性研究。

主要发现

  • 按因果推断假设区分,部分研究可能报告了混杂的治疗效应,而基于其设计更可能报告因果治疗效应的研究被单独识别。
  • RCT因mSASSS对变化敏感性低而难以用于测试axSpA的结构效应,现有文献主要为观察性研究。

关键数值与推荐

  • 脊柱结构损伤通常用改良Stoke强直性脊柱炎脊柱评分(mSASSS)量化。

临床怎么用

  • 临床解读bDMARDs对axSpA脊柱结构进展的观察性证据时,应结合因果推断假设评估研究设计,区分混杂效应与因果效应。

局限性

  • 现有文献主要为观察性研究,对因果关系的确定构成严重挑战;RCT因mSASSS敏感性低而难以实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Axial spondyloarthritis (axSpA) is a chronic rheumatic disease characterised by inflammation predominantly involving the spine and the sacroiliac joints. In some patients, axial inflammation leads to irreversible structural damage that in the spine is usually quantified by the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS). Available therapeutic options include biological disease-modifying antirheumatic drugs (bDMARDs), which have been proven effective in suppressing inflammation in several randomised controlled trials (RCT), the gold standard for evaluating causal treatment effects. RCTs are, however, unfeasible for testing structural effects in axSpA mainly due to the low sensitivity to change of the mSASSS. The available literature therefore mainly includes observational research, which poses serious challenges to the determination of causality. Here, we review the studies testing the effect of bDMARDs on spinal radiographic progression, making use of the principles of causal inference. By exploring the assumptions of causality under counterfactual reasoning (exchangeability, positivity and consistency), we distinguish between studies that likely have reported confounded treatment effects and studies that, on the basis of their design, have more likely reported causal treatment effects. We conclude that bDMARDs might, indirectly, interfere with spinal radiographic progression in axSpA by their effect on inflammation. Innovations in imaging are expected, so that placebo-controlled trials can in the future become a reality. In the meantime, causal inference analysis using observational data may contribute to a better understanding of whether disease modification is possible in axSpA.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Sepriano A, Ramiro S, van der Heijde D, et al. Biological DMARDs and disease modification in axial spondyloarthritis: a review through the lens of causal inference. RMD Open. 2021. PMID: 34253683. doi:10.1136/rmdopen-2021-001654

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。